Current Illinois CancerCare Clinical Trials

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Study Number: S2013

Study Summary:
This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments.

Status: Open

Peoria, Bloomington, Galesburg, Pekin, Washington

Study Coordinator(s)
  • Navigator Carrie, 309-243-3621
  • Navigator Ashton, 309-243-3611
  • Navigator Angie, 309-243-3613,

Study Link

« Search Again